Evidence map›Paper›PMID 35137176›Full record

SynthesisMutagenesis2022

The suitability of micronuclei as markers of relative biological effect.

Charlotte J Heaven, Hannah C Wanstall, Nicholas T Henthorn, John-William Warmenhoven, Samuel P Ingram, Amy L Chadwick, Elham Santina, Jamie Honeychurch, Christine K Schmidt, Karen J Kirkby and 3 more

Open access · hybridAbstract readMeta-Analysis
In one paragraph

Synthesis in Mutagenesis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Charlotte J HeavenDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, The University of Manchester, Oxford Road, M13 9PL Manchester, United Kingdom.
Hannah C WanstallManchester Academic Health Science Centre, The Christie NHS Foundation Trust, Wilmslow Road, M20 4BX Manchester, United Kingdom.ORCID 0000-0002-2992-1861
Nicholas T HenthornDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, The University of Manchester, Oxford Road, M13 9PL Manchester, United Kingdom.
John-William WarmenhovenDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, The University of Manchester, Oxford Road, M13 9PL Manchester, United Kingdom.
Samuel P IngramDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, The University of Manchester, Oxford Road, M13 9PL Manchester, United Kingdom.
Amy L ChadwickDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, The University of Manchester, Oxford Road, M13 9PL Manchester, United Kingdom.ORCID 0000-0002-7841-0507
Elham SantinaDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, The University of Manchester, Oxford Road, M13 9PL Manchester, United Kingdom.
Jamie HoneychurchDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, The University of Manchester, Oxford Road, M13 9PL Manchester, United Kingdom.
Christine K SchmidtDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, The University of Manchester, Oxford Road, M13 9PL Manchester, United Kingdom.
Karen J KirkbyDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, The University of Manchester, Oxford Road, M13 9PL Manchester, United Kingdom.
Norman F KirkbyDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, The University of Manchester, Oxford Road, M13 9PL Manchester, United Kingdom.
Neil G BurnetManchester Academic Health Science Centre, The Christie NHS Foundation Trust, Wilmslow Road, M20 4BX Manchester, United Kingdom.
Michael J MerchantDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, The University of Manchester, Oxford Road, M13 9PL Manchester, United Kingdom.
Manchester Academic Health Science Centre · GBUniversity of Manchester · GB

Funding

Cancer Research UK 28280Department of Health BRC-1215-20007Medical Research Council
6 · The paper itself

Abstract

Micronucleus (MN) formation is routinely used as a biodosimeter for radiation exposures and has historically been used as a measure of DNA damage in cells. Strongly correlating with dose, MN are also suggested to indicate radiation quality, differentiating between particle and photon irradiation. The "gold standard" for measuring MN formation is Fenech's cytokinesis-block micronucleus (CBMN) cytome assay, which uses the cytokinesis blocking agent cytochalasin-B. Here, we present a comprehensive analysis of the literature investigating MN induction trends in vitro, collating 193 publications, with 2476 data points. Data were collected from original studies that used the CBMN assay to quantify MN in response to ionizing radiation in vitro. Overall, the meta-analysis showed that individual studies mostly have a linear increase of MN with dose [85% of MN per cell (MNPC) datasets and 89% of percentage containing MN (PCMN) datasets had an R2 greater than 0.90]. However, there is high variation between studies, resulting in a low R2 when data are combined (0.47 for MNPC datasets and 0.60 for PCMN datasets). Particle type, species, cell type, and cytochalasin-B concentration were suggested to influence MN frequency. However, variation in the data meant that the effects could not be strongly correlated with the experimental parameters investigated. There is less variation between studies when comparing the PCMN rather than the number of MNPC. Deviation from CBMN protocol specified timings did not have a large effect on MN induction. However, further analysis showed less variation between studies following Fenech's protocol closely, which provided more reliable results. By limiting the cell type and species as well as only selecting studies following the Fenech protocol, R2 was increased to 0.64 for both measures. We therefore determine that due to variation between studies, MN are currently a poor predictor of radiation-induced DNA damage and make recommendations for futures studies assessing MN to improve consistency between datasets.

Indexed as

CytokinesisLymphocytesDNA DamageMicronucleus TestsRadiation, Ionizingcytochalasin-BDNA damagemicronucleiradiotherapy

Identifiers

PMID35137176
PMCPMC8976228
OpenAlexW4206664580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.